Login to Your Account

FoldRx's Tafamidis Puts Crimp in Fatal Fibril Disease's March

By Donna Young

Wednesday, July 22, 2009
Results from privately held FoldRx Pharmaceuticals Inc.'s pivotal Phase II/III trial showed that tafamidis (Fx-1006A) significantly halts disease progression and reduces the burden of disease in patients with transthyretin (TTR) amyloid polyneuropathy (ATTR-PN), a fatal progressive neurodegenerative orphan disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription